Welcome

Paradigm Biopharma Ltd (ASX:PAR) is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.

READ MORE

Paradigm Shift

Repurposing

Established drugs can be repurposed for new clinical indications for unmet medical needs when protected by strong intellectual property. Historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs.

READ MORE

Understanding complexity

Life is complex! For every diagnosis, there are multiple factors and biological interactions involved. We develop therapeutics targeting multiple pathways involved in injury or on the road to disease producing better outcomes for patients.

READ MORE

We develop therapeutics targeting multiple pathways involved in injury

Our focus

Pentosan Polysulphate Sodium (PPS)

We focus on PPS because this FDA approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and respiratory disease.

READ MORE

Inflammation

Inflammation is a complex biological response to injury, infection or allergy, which has short and long term components mediated by factors produced by immune cells.

READ MORE

Announcements

Paradigm reports successful Phase 2 Clinical Trial

18th December 2018

Paradigm Biopharmaceuticals Ltd is pleased to announce it has met its primary endpoint of its phase 2b randomised double-blind placebo-controlled multi-centre clinical trial.

READ MORE

Presentation of Phase 2 Clinical Trial results

18th December 2018

Please access link for company presentation via our ASX release.

READ MORE

Paradigm reports consistent OA pain reduction

7th December 2018

Paradigm Biopharmaceuticals Ltd is pleased to announce consistent reduction in pain (on average), from an additional 38 patients with osteoarthritis treated with injectable Pentosan Polysulfate Sodium (iPPS) under the Therapeutic Goods Administration Special Access Scheme.

READ MORE

Inflammation is a complex biological response to injury, infection or allergy

Key Statistics

Alpharirus

Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.

*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016

Osteoarthritis (OA)

OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.

*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September

Bone Marrow Edema (BME)

Worldwide hip & knee surgical implant market is $16.7 billion, will be $33 billion by 2022. Acute joint injury leads to osteoarthritis.

Bone Marrow Edema (BME)

>50% top ranked skiers have injured knee ligaments (women 5x more susceptible than men)

Company Pipeline

Research & Development

Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.

READ MORE